Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit

Traders Union
All News
Companies
Lineage Cell OpRegen trial results

Top Stories

Editors' Picks

Crypto

Financial News

Currencies

Market Voices

Companies

Regulators

Central Banks

Artem Shendetskii

04.05.2026

Lineage Cell Therapeutics presents 3-year Phase 1-2a OpRegen trial results in geographic atrophy at summit — Lineage Cell OpRegen trial results

Lineage Cell Therapeutics revealed new results from its 3-year Phase 1-2a clinical study of OpRegen (RG6501) in patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

The findings, presented at the Retinal Therapeutics Innovation Summit 2026 on behalf of Roche and Genentech, included imaging data and suggest continued progress in regenerative therapies for advanced retinal disease.

Loading...

The tweet was deleted by the author.

But we saved everything 🙂.

Lineage Cell Therapeutics has expanded its focus within ophthalmic diseases in recent years. The company previously launched COR1 to address corneal endothelial diseases, targeting patients affected by FECD. The launch highlights Lineage's involvement in regenerative therapy programs for conditions affecting vision.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.

Did you like the article?

Editor's Picks for You

Intel's comeback: Apple, Trump and the AI bet

By Mikhail Vnuchkov
19 hours ago

Intel's comeback: Apple, Trump and the AI bet

Editors' Picks

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

By Oleg Tkachenko
Yesterday

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Editors' Picks

Toncoin becomes Gram: Why Durov restored token's original name

By Anastasiia Chabaniuk
16.06.2026

Toncoin becomes Gram: Why Durov restored token's original name

Editors' Picks

All Editors' Top Picks

Latest Lineage Cell News

Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit

By Yulia Slavina
15.06.2026

Lineage Cell Therapeutics joins panel on novel treatments at Clinical Trials at the Summit

Companies

Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect

By Parshwa Turakhiya
28.05.2026

Lineage Cell Therapeutics spotlights CEO participation in fireside chat with HCWCO at BioConnect

Companies

Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies

By Elena Nikulina
14.05.2026

Lineage Cell Therapeutics featured in European Pharmaceutical Review report on scalable cell therapies

Companies

All Lineage Cell News

Mikhail Vnuchkov
19 hours ago

Intel's comeback: Apple, Trump and the AI bet

Oleg Tkachenko
Yesterday

Bitcoin price prediction based on RSI: Is BTC poised for a new rally?

Anastasiia Chabaniuk
16.06.2026

Toncoin becomes Gram: Why Durov restored token's original name

Kyle Torpey
15.06.2026

Why Tether flipping Ethereum is a pivotal moment for crypto

Eugene Komchuk
15.06.2026

MiCA deadline: Why crypto companies are leaving Europe

Andreas Kristo
20 min ago

Harvard Business School faculty list Volatility Machine for summer 2026, Michael Pettis writes

Elena Nikulina
30 min ago

Terrorist groups could receive $324 billion, Mark R. Levin warns

Hanna Syniavska
1 hour ago

TIME suggested retiring 401k in 2009, Ryan Detrick adds

Andrey Mastykin
1 hour ago

Company dominance fluctuates through cycles and bubbles, Callum Thomas notes

Anastasiia Chabaniuk
1 hour ago

Concerns about Social Security are unfounded if stock valuations are reasonable, Dean Baker points out

Weekly Top Bonuses

Capitalcore

up to $2,500
deposit bonus for all clients

Your capital is at risk.

Top News

Olga Shendetskaya
12 hours ago

Goldman sees Warsh remarks as new risk for two-year Treasuries

Goldman sees Warsh remarks as new risk for two-year Treasuries

Andrey Mastykin
14 hours ago

G7 calls for stronger fight against North Korean crypto theft

G7 calls for stronger fight against North Korean crypto theft

Eugene Komchuk
14 hours ago

First oil tankers cross Strait of Hormuz after U.S.-Iran agreement

First oil tankers cross Strait of Hormuz after U.S.-Iran agreement

Ivan Andriyenko
19 hours ago

U.S. futures rise as investors weigh Iran deal and Fed

U.S. futures rise as investors weigh Iran deal and Fed

Mikhail Vnuchkov
19 hours ago

Intel's comeback: Apple, Trump and the AI bet

Intel's comeback: Apple, Trump and the AI bet

Top 5 companies for you

United States

Live News

Anton Kharitonov
Now

Microsoft balances AI investment with investor expectations

Anton Kharitonov
Now

Apple maintains strong fundamentals despite market pressures

Mykhailo Ihnatenko
Now

SPCX pulls back for the first time: Can SpaceX optimism sustain rally?

Anton Kharitonov
Now

Bitcoin tests major support after hawkish Fed signal

Mykhailo Ihnatenko
Now

Intel jumps on Apple foundry hopes: Can INTC reach new highs?

© IAFT Ltd., 2010-2026 All rights to the website are owned by IAFT Ltd.,
Registration number - HE 336186

Risk disclosure:

Information on the TradersUnion.com website is for informational purposes only and does not constitute any motive or suggestion to visitors to invest money. Moreover, we hereby warn you that trading on the Forex and CFD markets is always a high risk. According to the statistics, 75-89% of customers lose the funds invested and only 11-25% of traders earn a profit. Trading in futures and options carries substantial risk of loss and is not suitable for every investor.

That is why you should only invest money that you are prepared — or can afford — to lose at such high risks. Tradersunion.com does not provide any financial services, including investment or financial advisory services. Also, the Traders Union is not a broker and does not get money for trading in the Forex or CFD markets. Our website only provides information on brokers and the markets and helps its users to select the best brokerage company based on detailed information and objective analysis of brokers.
Disclaimer:

Traders Union (TradersUnion.com) shall not be liable for the consequences of trading decisions made by the Client and for the possible loss of his capital resulting from the use of this website and information published on it.

Forex market, CFD and cryptocurrency trading involves high risks and is not suitable for everyone. Before investing money, you need to adequately assess the level of your expertise and be aware of the risks, particularly in the context of trading with leverage. The information on this website is not intended for distribution or use by any person in any country or jurisdiction, where such distribution or use would be in violation of the local law or regulation. Any payments by Traders Union (TradersUnion.com) to the users of our website shall be legally interpreted solely as an incentive on our part for the activity on the website in the form of a deduction of a part of the advertising income; they shall not be a subject of any claims of our users or our obligations, a subject of disputes, as well as cannot be considered in relation to the services provided to users by brokers, both in fact and in their completeness and volume. The administration of the website shall not be liable for the content of user comments and reviews about the companies and shall not verify whether the authors of the reviews are indeed real clients of a specific company. All reviews, both negative and positive are published on the website without verification of their reliability; only offensive reviews that call for violence or any kind of discrimination and also reviews published from one group of IP addresses are moderated and removed. The authors of the materials shall be fully liable for the accuracy, completeness and impartiality of any information in the articles and reviews, including in the context of their use or mention of any brand names or trademarks. All mentions of the names of companies and their brands in any materials on the website shall be made in the context of communication of socially important information to the people about their activities by independent journalists, who are the authors. All evaluations and indicators on the website express the subjective opinion of the authors of the reviews (articles) and shall not be viewed as accurate statements and be a subject of disputes and claims against Traders Union.
Disclosure of advertisers and revenues:

All the services on the Tradersunion.com website are free for you to use. Our team spends thousands of hours per annum researching brokers and gathering information about them to help investors all over the world to choose reliable companies and to avoid fraudsters.

Indeed, the curating, sourcing, and organization of this process requires substantial financial investment by Tradersunion.com, which the website earns in the form of advertising payments. There are two types of advertising services on the website — direct advertising or partner (broker) participation programs. However, no services purchased by our partners shall affect the recommendations on our website, or our opinions, or ratings. Our ratings are based on our objective rating criteria and methodology; and the results are always equally and fairly applied to each broker. The work of our content authors and research groups does not involve any interaction with our advertisers and they do not have access to data concerning the amount of advertising purchased. For over 10 years we consider our independence, absolute openness, and objectivity as our main priority. Please follow the links to each of our affiliated broker’s websites. This will help Tradersunion.com to continue to provide our services to you for free.